文献速递眼整形与眼眶神经眼科

Satralizumab治疗甲状腺眼病的疗效与安全性:III期SatraGO-1和SatraGO-2随机试验第24周结果

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials.
PubMed 文献 · Ophthalmology · 2026-09-07

两项设计相同的72周双盲安慰剂对照III期试验评估了抗IL-6受体抗体satralizumab在甲状腺眼病(TED)患者中的疗效与安全性。活动性TED患者中,satralizumab组第24周眼球突出缓解、CAS降低、疾病失活和复视改善的比例均高于安慰剂组,但部分比较未达统计学显著;药物耐受性良好。

要点

  • 活动性TED中satralizumab提高眼球突出缓解率,SatraGO-2达统计学显著。
  • CAS降低和疾病失活比例在两项试验中均显著优于安慰剂。
  • satralizumab耐受性良好,严重不良事件、停药和感染率低。

核心结论

  • Satralizumab在TED患者中显示眼球突出、CAS和复视的临床有意义改善,且安全性良好。

研究设计与样本

  • SatraGO-1和SatraGO-2为设计相同的72周双盲安慰剂对照多中心III期试验,两阶段随机分组。
  • 纳入年龄≥18岁、活动性中重度TED(CAS≥3且≤12个月)或非活动性TED(CAS<3且≥6个月)患者。
  • SatraGO-1共131例、SatraGO-2共127例,按1:1随机接受皮下satralizumab或安慰剂负荷剂量(第0、2、4周),随后每4周给药至第20周。

主要发现

  • 活动性TED中,satralizumab组眼球突出缓解率SatraGO-1为49.0% vs 31.2%(P=0.0715),SatraGO-2为52.9% vs 23.4%(P=0.0011)。
  • CAS降低≥2分的比例SatraGO-1为78.0% vs 54.9%(P=0.0120),SatraGO-2为89.6% vs 63.3%(P=0.0009)。
  • CAS为0或1的比例SatraGO-1为68.0% vs 45.1%(P=0.0146),SatraGO-2为68.8% vs 40.8%(P=0.0042)。
  • 复视改善≥1级的比例SatraGO-1为44.4% vs 34.4%(P=0.3371),SatraGO-2为60.7% vs 25.8%(P=0.0044)。
  • 合并活动性和非活动性TED人群观察到相似的临床获益;satralizumab耐受性良好,严重不良事件、治疗中断和感染率低,无严重感染。

关键数值与推荐

  • 主要终点为活动性TED患者第24周眼球突出应答率(较基线减少≥2 mm)。
  • 次要终点包括第24周CAS降低≥2分、疾病失活(CAS为0或1)和复视改善≥1级的比例。

临床怎么用

  • Satralizumab可作为TED患者一种有效且耐受性良好的治疗选择,通过抑制IL-6通路改善眼球突出、CAS和复视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the primary efficacy and safety of satralizumab, an anti-interleukin-6 receptor antibody, in patients with thyroid eye disease (TED). DESIGN: SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828) are identically designed, 72-week, double-masked, placebo-controlled, multicenter, 2-stage randomization phase III trials. PARTICIPANTS: Aged ≥18 years with active, moderate-to-severe TED (Clinical Activity Score [CAS] ≥3 for ≤12 months) or inactive TED (CAS <3 for ≥6 months). METHODS: Participants (SatraGO-1: N = 131; SatraGO-2: N = 127) were randomized 1:1 to receive loading doses of subcutaneous satralizumab or placebo at weeks 0, 2, and 4, followed by an every-4-week dosing regimen through week 20 (part 1). MAIN OUTCOME MEASURES: The primary end point was the proportion of participants with active TED who achieved a proptosis response (≥2-mm reduction from baseline) at week 24. Secondary end points included the proportion of participants with a ≥2-point CAS reduction, disease inactivation (CAS of 0 or 1), and an ≥1-grade diplopia reduction at week 24. Efficacy outcomes were also reported for the combined active and inactive TED population. Safety was assessed in all participants exposed to the study treatment. RESULTS: In participants with active TED, the satralizumab arm of both trials consistently showed an increased proportion achieving a proptosis response (SatraGO-1: 49.0% vs. 31.2%; P = 0.0715; SatraGO-2: 52.9% vs. 23.4%; P = 0.0011), CAS reduction (SatraGO-1: 78.0% vs. 54.9%; P = 0.0120; SatraGO-2: 89.6% vs. 63.3%; P = 0.0009), CAS of 0 or 1 (SatraGO-1: 68.0% vs. 45.1%; P = 0.0146; SatraGO-2: 68.8% vs. 40.8%; P = 0.0042), and diplopia reduction (SatraGO-1: 44.4% vs. 34.4%; P = 0.3371; SatraGO-2: 60.7% vs. 25.8%; P = 0.0044) compared with placebo, although not all comparisons reached statistical significance. Similar clinical benefits were observed in the combined active and inactive TED population. Satralizumab was well tolerated, with low rates of serious adverse events, treatment discontinuations, and infections, and no serious infections. CONCLUSIONS: Satralizumab demonstrated clinically meaningful improvements in proptosis, CAS, and diplopia and had a favorable safety profile in participants with TED. Interleukin-6 pathway inhibition with subcutaneous satralizumab represents an efficacious and well-tolerated treatment option for patients with TED. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Briceño CA, Idowu OO, Khong JJ, et al. Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials. Ophthalmology. 2026. PMID: 42705581. doi:10.1016/j.ophtha.2026.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。